Britannia Life Sciences Inc. (formerly RISE Life Science Corp.)：高管交易动态
Britannia Life Sciences Inc. (formerly RISE Life Science Corp.)归属医疗保健行业。公司董事和高级管理人员通过SEDI申报交易。过去一年很平静：Britannia Life Sciences Inc. (formerly RISE Life Science Corp.)没有一份高管申报。上一份申报发布于2021年12月1日。
回溯至覆盖起点2021年，高管共申报2笔买入和0笔卖出。
以上数据均来自SEDI发布的申报，描述的是过去的情况，不代表未来股价走势，也不构成投资建议。
该评分只在所属市场内对买入进行排名。仅在经过回测的策略范围内的交易所提供建议仓位；其他市场的信号仍处于观察状态。并非投资建议。
透明的价值 + 质量排名，独立于内部人交易信号。
财务数据
财年 2026财年截至 2026年3月 · cache
- 47,482 股@ CA$0.161.6% 占其流量股票TSXSEDI:3839916
- 294,352 股@ CA$0.169.7% 占其流量股票TSXSEDI:3839914
- 750,000 股@ CA$0.2944.5% 占其流量股票TSXSEDI:3836139标准退出：2022年2月16日 (T+90)
- 800,000 股@ CA$0.2744.2% 占其流量股票TSXSEDI:3836138标准退出：2022年2月16日 (T+90)
- 股票TSXSEDI:3836140
- 股票TSXSEDI:3835323
- 股票TSXSEDI:3835325
- 股票TSXSEDI:3833253
- 股票TSXSEDI:3833237
- 股票TSXSEDI:3833215
10 条申报中的 10 条
About Britannia Life Sciences Inc. (formerly RISE Life Science Corp.)
The 10 filings of Britannia Life Sciences Inc. (formerly RISE Life Science Corp.) fit into two weeks of November 2021. On November 18, 2021, Peter James Shippen, filed as 10% holder, director and senior officer, bought for EUR 152,294 then EUR 151,243, or EUR 303,537 in total: those are the only 2 purchases on file, and there is no sale. Shippen signs 7 of the 10 filings, including the 2 purchases. Three other senior officers lodge one filing each: Sarah Zilik, Boris Novansky and Mark Bowes-Cavanagh, the last also a 10% holder. Eight of the filings are of a kind other than purchase or sale. In all, 4 filers appear in the record. Transactions run from November 12 to November 26, 2021, and the filings were published between November 17 and December 1, 2021, a median of 6 days after the trade. The Canadian health care company, listed in Toronto, has a market capitalisation of CAD 10.7 million, with 34.4% held by insiders. No filing falls in the last twelve months.
